10月7日，药明生物开盘下跌3.11%，报56.1港元，成交额1.3亿港元。该股前一日盘中曾上涨3.16%，今日低开显示短线获利回吐压力。
消息面上，公司近期基本面表现稳健。此前披露的中期业绩显示，营收117.87亿元，经调整净利润39.37亿元，毛利率提升至46.2%，XDC外部销售同比增长37.8%。同时公司注销约3982万股已回购股份，客观上减少流通盘。然而今日CXO板块整体走弱，英矽智能跌5.06%、昭衍新药跌4.35%、晶泰控股跌2.47%，板块情绪对药明生物形成拖累。
药明生物技术有限公司是一家主要从事向生物制剂行业客户提供生物发现、开发及生产端到端解决方案及服务的投资控股公司，业务涵盖生物药及药明合联（XDC）两大分部。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.